Pasteur Institute of Iran is a medical research center located in Tehran, Iran. The institute is one of the oldest leading research and public health centers in Iran and the Middle East, established in 1920 following an agreement between the Institute Pasteur of Paris and the Iranian government. The Pasteur Institute of Iran was developed with the help of a land donation from Abdol-Hossein Farmanfarma. Its mission is to support advanced research and to provide innovative programs in basic and applied medical sciences, and production of biopharmaceuticals and diagnostic kits with special emphasis on infectious diseases. It meets the specialized and scientific health demands of the local community and tries to establish a link between applied research and industry. Pasteur Institute is a leading regional facility in the development and manufacture of vaccines. The institute has a total staff of 1300 in its 28 departments and 5 branches in different cities of Iran, which are active in different areas of medical and pharmaceutical biotechnology. There are about 300 PhDs and M.Sc graduates.This institute is a center that provides public health services and has played a significant role in the prevention and control of infectious diseases in Iran and the world during approximate one hundred years of its activities The establishment of Pasteur Institute of Iran in one century of activity has had many positive effects on public health in Iran. Through its brilliant activities and developing both quality and quantity in its services including conducting research studies associated with the control of infectious diseases, producing vaccines and biological products, launch of public vaccination, holding national and international training course on emerging and reemerging infectious diseases, the Institute has taken great strides in preventing and controlling infectious diseases, and has gained significant credibility and reputation nationally and internationally.This institute can be a useful model for the country and the region, and it is hoped to continue its important roles in the field of infectious diseases as an effective research and production unit in the second century of its work.
The use of Exosomes (EXOs) to induce the regeneration of hair follicles has received much attention today. The present study was conducted to survey the effects of Citrus limon-derived EXOs (EXO-CLs) on promoting hair growth. EXOs were isolated from citrus limon by the filtration technique. According to NanoSight DynamicLight Scattering and Scanning Electron Microscopy, the extracted EXOs had a size of 147 nm and a spherical morphology. The flow cytometry analysis showed the expression of surface markers CD9 (64.6
Myocardial infarction (MI) represents a major component of cardiovascular disease, primarily due to severe energy depletion in ischemic tissue. Extracellular vesicles (EVs) have recently emerged as promising cell-free nanocarriers capable of targeted delivery and intercellular communication. Leveraging these advantages, engineered EVs were investigated in this study as a direct ATP-delivery platform to cardiomyocytes. EVs were functionalized with an anti-myosin antibody to form targeted extracellular vesicles (T-EVs) and subsequently loaded with ATP, generating T-ATP-EVs for selective energy transfer to damaged myocardium. We study viability and apoptosis of ischemia cells by alamar Blue and flowcytometry (annexin-PI) under hypoxic condition in vitro also we use cardiac function, infarct size, and the expression of troponin and α-actin four weeks after MI on MI rat model in vivo for assessment cardiac repair. The results indicate that, compared with no treatment, the use of T-ATP-EVs enhances the viability of hypoxic cells by 46 T-ATP-EVs increase cardiomyocyte viability by 46
Targeting multiple neoepitopes by vaccines have the potential to circumvent intratumor clonal heterogeneities and minimize the chance of tumor escape. Due to immunostimulatory properties of outer membrane vesicles, their ability to target lymph nodes, as well as unaltered conformation of the loaded antigens in recombinant OMVs (rOMVs), they offer as promising vaccine platforms. Herein, we aimed to evaluate the therapeutic and antimetastatic potential of ClearColiTM-derived rOMVCT−26 polytope encoding CT-26 polytope and compare the induced immunity by the CT-26 polytope as a recombinant protein or as rOMVCT−26 polytope. Herein, BALB/c mice were challenged subcutaneously by CT-26 cells and treated with OMV, rOMVCT−26 polytope, CT-26 polytope, CT-26 polytope + rOMVCT−26 polytope, CT-26 polytope + alum. Lung metastasis was evaluated in treated mice after intravenous CT-26 challenge. Treatment with CT-26 polytope + rOMVCT−26 polytope resulted in the highest level of specific IgG2a titer and the greatest IFN-γ/IL-10 and TNF-α/IL-10 ratios, demonstrating their superior capacity to induce Th1 immunity. rOMVCT−26 polytope alone or in combination with CT-26 polytope resulted in substantial tumor growth delay, and complete prevention of lung metastasis. In contrast, CT-26 polytope + alum and CT-26 polytope elicited higher IgG1 levels, a Th2-biased response, lower IFN-γ/IL-10 and TNF-α/IL-10 ratios. Moreover, despite fewer lung metastases than PBS in the CT-26 polytope-treated group, CT-26 polytope couldn’t completely suppress lung metastasis. Altogether, delivery of poly-neoepitopes by rOMVCT−26 polytope resulted in considerable anti-tumor and antimetastatic effect in CT-26 therapeutic colon carcinoma model compared to its application as recombinant protein and consequently showed potential as personalized therapeutic CRC vaccines.
BACKGROUND:Hypercholesterolemia is a common metabolic disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) levels, a major risk factor for cardiovascular disease. MicroRNAs (miRNAs) are key post-transcriptional regulators of gene expression and lipid metabolism. METHODS AND RESULTS:In this study, in silico analysis revealed that miR-30b-3p could potentially target Apolipoprotein B (APOB), Proprotein convertase subtilisin/kexin type 9 (PCSK9), and Cholesteryl ester transfer protein (CETP). miR-30b-3p binding sites in the 3'-untranslated regions (UTRs) of PCSK9, APOB, and CETP were predicted and validated by dual luciferase reporter assays. Luciferase assays indicated significant reducing reporter activity (PCSK9: 49%, APOB: 39%, CETP: 86%). miR-30b-3p overexpression decreased mRNA levels of PCSK9, APOB, and CETP, with reduced PCSK9/ApoB protein but unchanged CETP protein. miR-30b-3p could play a regulatory role in lipid metabolism by targeting PCSK9 and APOB, reducing LDL levels in hepatocytes. Huh-7 cells underwent miR-30b-3p overexpression via lentiviral transduction and the expression of genes/proteins were assessed by quantitative PCR and western blot. LDL and high-density lipoprotein (HDL)-associated proteins in the culture media supernatant were measured to evaluate functional lipid changes. LDL-associated protein decreased in the conditioned medium, whereas HDL-associated readouts remained unchanged, leading to a lower LDL/HDL ratio, indicating impact on lipid homeostasis. CONCLUSIONS:This study aimed to investigate the effects of miR-30b-3p on the expression and function of the mentioned genes and the outcome of this intervention on lipid metabolism. These findings propose miR-30b-3p as a promising therapeutic candidate for hypercholesterolemia, warranting further in vivo validation.
Brucellosis is a common zoonosis, affecting animals and humans. Given the high prevalence of brucellosis, as well as the challenges associated with the animal vaccines, there is a need to develop effective vaccines against it. In this study, a Brucella vaccine candidate was developed based on niosome nanoparticles encapsulating BP26 protein from Brucella melitensis. Cloning of amplified bp26 gene, cloning in pET28a-BL21 (DE3), and protein expression were done by optimized protocols. The properties of the synthesized niosome nanoparticles were evaluated using dynamic light scattering (DLS) and electron microscopy. Then, the entrapment efficacy, release profile, and effectiveness of BP26-encapsulated niosomes were assessed in vitro and in vivo. Analyses indicated BP26-encapsulated niosomes with an average size of 265.5 nm, entrapment efficacy of 95.4
